Clinical Updates from San Diego

Clinical Brief 1 – Subsequent-Line Ciltacabtagene Autoleucel for Multiple Myeloma: Updated Results From the Phase 2 CARTITUDE-2 Trial

References

Tweet 2 Reference:

Hillengass J, Cohen AD, Agha ME, et al. 1021 The phase 2 CARTITUDE-2 trial: updated efficacy and safety of ciltacabtagene autoleucel in patients with multiple myeloma and 1–3 prior lines of therapy (cohort A) and with early relapse after first line treatment (cohort B). Presented at: ASH; December 9–12 2023; San Diego, CA. https://www.congresshub.com/Oncology/ASH2023/Cilta-cel/Hillengass#slides

Additional References:

ABECMA® (idecabtagene vicleucel). Prescribing information. Bristol-Myers Squibb. Approved 2021. Revised March 2021. https://www.fda.gov/media/147055/download

Biltibo E, Berdeja JG. SOHO state of the art updates and next questions: BCMA-directed CAR T-cells: early results and future directions. *Clin Lymphoma Myeloma Leuk*. 2023;23(5):310-321. doi:10.1016/j.clml.2023.01.017

CARVYKTI™ (ciltacabtagene autoleucel). Prescribing information. Janssen Biotech, Inc. Approved 2022. Revised February 2022. https://www.fda.gov/media/156560/download

Cohen AD, Parekh S, Santomasso BD, et al. Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. *Blood Cancer J*. 2022;12(2):32. doi:10.1038/s41408-022-00629-1

GSK. GSK provides an update on Blenrep (belantamab mafodotin-blmf) US marketing authorisation. Updated November 22, 2022. Accessed January 30, 2023. https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-blenrep-us-marketing-authorisation/

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Multiple Myeloma (v3.2023). Updated December 8, 2022. Accessed February 28, 2023. https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf

Parikh RH, Lonial S. Chimeric antigen receptor T-cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice. *CA Cancer J Clin*. 2023;doi:10.3322/caac.21771

San-Miguel J, Dhakal B, Yong K, et al. Cilta-cel or Standard Care in lenalidomide-refractory multiple myeloma. *N Engl J Med*. 2023;389(4):335-347. doi:10.1056/NEJMoa2303379

Sidiqi MH, Corradini P, Purtill D, et al. Efficacy and safety in patients with lenalidomide-refractory multiple myeloma after 1-3 prior lines who received a single infusion of ciltacabtagene autoleucel as study treatment in the phase 3 CARTITUDE-4 trial. *Blood*. 2023;142(Supplement 1):4866-4866. doi:10.1182/blood-2023-178778

TECVAYLI™ (teclistamab-cqyv). Prescribing information. Janssen Biotech, Inc. Approved 2022. Revised October 2022. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process

Glossary

AE, adverse event
AESI, adverse event of special interest
ASCT, autologous stem cell transplant
BCMA, B-cell maturation antigen
CAR T, chimeric antigen receptor T cell
CI, confidence interval
Cilta-cel, ciltacabtagene autoleucel
CRS, cytokine release syndrome
DOR, duration of response
HRQOL, health-related quality of life
LEN, lenalidomide
LOT, line of therapy
MRD, minimal residual disease
NDMM, newly diagnosed multiple myeloma
NE, not evaluated
ORR, overall response rate
OS, overall survival
PFS, progression-free survival
RRMM, relapsed/refractory multiple myeloma
TE, treatment emergent
TTBR, time to best response
Tox, toxicity
w/, with